RxDoctor Payments Data

Lauren Just

Family · Cheshire, CTNPI 1548833478

Payments from drug & device makers

$1,025in general payments, 2019–2025

Across 51 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$403
  • Teva Pharmaceuticals USA, Inc.$145
  • AbbVie$101
  • Kyowa Kirin, Inc.$95
  • Pfizer$89
  • Neurocrine Biosciences, Inc.$59
  • plus $134 from 4 others

What the payments were for

  • Food & beverage$1,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,025 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$60,988
Medicare patients
260
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate53$437,599
GocovriAmantadine Hcl62$250,832
AustedoDeutetrabenazine18$247,683
RytaryCarbidopa/Levodopa122$183,613
NourianzIstradefylline75$156,464
NuplazidPimavanserin Tartrate20$131,243
OngentysOpicapone86$90,070
NeuproRotigotine16$34,000
InbrijaLevodopa12$31,129
XadagoSafinamide Mesylate13$27,811
HorizantGabapentin Enacarbil23$27,716
LinzessLinaclotide20$16,837
Carbidopa-LevodopaCarbidopa/Levodopa479$14,689
AmantadineAmantadine Hcl122$7,920
Carbidopa-Levodopa ErCarbidopa/Levodopa232$7,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$59$527,669139 claims
MDD US Operations, LLCGocovri$403$250,83262 claims
Teva Pharmaceuticals USA, Inc.Austedo$145$247,68318 claims
Kyowa Kirin, Inc.Nourianz$95$156,46475 claims
Acadia Pharmaceuticals IncNuplazid$18$131,24320 claims
AbbVieLinzess$101$16,83720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in Cheshire

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →